Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.
The aim of this study was to compare the in vitro susceptibility of Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia to three fluoroquinolones. The minimum inhibitory concentrations (MICs) to ciprofloxacin, levofloxacin and moxifloxacin were examined by E-test® for a total of 40 K. pneumoniae strains, 40 S. maltophilia strains and 40 P. aeruginosa strains. Then, the bactericidal activity of these fluoroquinolones was investigated on five strains of each bacterial species by means of time-kill curves. For K. pneumoniae and P. aeruginosa, the distance of the measured MIC from the clinical break-point is a good indicator of the bactericidal activity for ciprofloxacin and levofloxacin as obtained in our experiments. The lower the MIC, the better the bactericidal activity in term of CFU Log decreases. If MIC of ciprofloxacin and levofloxacin against the considered bacteria are far from clinical breakpoint, these two antibiotics are equivalent. According to our MIC50 and modal MIC, the breakpoints of both ciprofloxacin and levofloxacin seem to be somewhat high and data suggest reducing them. On S. maltophilia, none of the tested antibiotics showed a satisfactory activity.
Institute of Bacteriology, Faculty of Medicine, University of Strasbourg and Strasbourg University Hospital, Strasbourg, France.
Antoine
A
Grillon
Institute of Bacteriology, Faculty of Medicine, University of Strasbourg and Strasbourg University Hospital, Strasbourg, France.
Frédéric
F
Schramm
Institute of Bacteriology, Faculty of Medicine, University of Strasbourg and Strasbourg University Hospital, Strasbourg, France.
Magali
M
Kleinberg
Institute of Bacteriology, Faculty of Medicine, University of Strasbourg and Strasbourg University Hospital, Strasbourg, France.
François
F
Jehl
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology*; D024841:Fluoroquinolones / Q000494:pharmacology*; D020128:Inhibitory Concentration 50; D007711:Klebsiella pneumoniae / Q000187:drug effects*; D064704:Levofloxacin / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D020615:Stenotrophomonas maltophilia / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D002939:Ciprofloxacin; D064704:Levofloxacin; D000077266:Moxifloxacin